Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma

被引:24
作者
Martinelli, G
Laszlo, D
Bertolini, F
Pastano, R
Mancuso, P
Calleri, A
Vanazzi, A
Santoro, P
Cavalli, F
Zucca, E
机构
[1] European Inst Oncol, Dept Hematol Oncol, I-20141 Milan, Italy
[2] Oncol Inst So Switzerland, Bellinzona, Switzerland
关键词
low grade; non-Hodgkin's lymphoma; chlorambucil; rituximab;
D O I
10.1046/j.1365-2141.2003.04586.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We investigated the toxicity and efficacy of the chimaeric anti-CD20 antibody rituximab in combination with standard-dose chlorambucil in newly diagnosed and relapsed/refractory indolent B-cell lymphoma patients. A total of 29 patients (15 newly diagnosed and 14 relapsed/refractory) with low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL) were included in this phase II study. Therapy consisted of chlorambucil 6 mg/m(2)/d for 6 consecutive weeks in combination with a standard 4-weekly rituximab administration schedule in the induction phase. Patients responding to the induction therapy received four additional cycles with chlorambucil (6 mg/m(2)/d for 2 weeks/month) plus rituximab (once a month). Twenty-six patients (89%) completed the treatment; only one patient discontinued treatment because of haematological toxicity. At the end of the study, the dose of chlorambucil had to be reduced in seven patients (27%) and six patients (23%) required a delay in further treatment, as a result of toxicity during consolidation therapy. Only one patient was withdrawn from the study because of progressive disease; the 27 patients evaluable for response at the end of consolidation achieved a clinical response (63% complete response and 26% partial response). A significant CD4(+) and CD56(+) depletion was observed after induction and during consolidation therapy; two herpes zoster virus infections and one perianal abscess represented major infectious morbidities registered during the study. Based on our preliminary data, the combination of chlorambucil with rituximab seemed to be well tolerated and active. Its definitive role in the treatment of low-grade NHL should be further evaluated in randomized trials.
引用
收藏
页码:271 / 277
页数:7
相关论文
共 26 条
[1]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[2]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[3]  
Coiffier B, 1998, BLOOD, V92, P1927
[4]   Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy [J].
Czuczman, MS ;
Grillo-López, AJ ;
White, CA ;
Saleh, M ;
Gordon, L ;
LoBuglio, AF ;
Jonas, C ;
Klippenstein, D ;
Dallaire, B ;
Varns, C .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :268-276
[5]  
Davis TA, 1999, CLIN CANCER RES, V5, P611
[6]   Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs [J].
Demidem, A ;
Lam, T ;
Alas, S ;
Hariharan, K ;
Hanna, N ;
Bonavida, B .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1997, 12 (03) :177-186
[7]  
EZDINLI EZ, 1965, JAMA-J AM MED ASSOC, V191, P100
[8]   Bcl-2-related antisense therapy [J].
Gutiérrez-Puente, Y ;
Zapata-Benavides, P ;
Tari, AM ;
López-Berestein, G .
SEMINARS IN ONCOLOGY, 2002, 29 (03) :71-76
[9]   Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma [J].
Hainsworth, JD ;
Litchy, S ;
Burris, HA ;
Scullin, DC ;
Corso, SW ;
Yardley, DA ;
Morrissey, L ;
Greco, FA .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) :4261-4267
[10]  
Hainsworth JD, 2000, BLOOD, V95, P3052